\-\ Texto\\:\\ \ \(0\)\
\-\ there\\ is\\ abnormal\\ signal\\ in\\ the\\ l3\\ vertebral\\ body\\,\\ which\\ is\\ associated\\ with\\ mild\\ compression\\ fracture\\ deformity\\.\\ there\\ is\\ extensive\\ involvement\\ of\\ the\\ soft\\ tissue\\ with\\ expansion\\ into\\ the\\ anterior\\ soft\\ tissues\\.\ \(0\)\
\-\ metastatic\\ renal\\ cell\\ carcinoma\ \(1\)\
\-\ metastasis\ \(206\)\
\-\ myeloma\ \(71\)\
\-\ lymphoma\ \(373\)\
\-\ leukemia\ \(70\)\
\-\ neuroblastoma\ \(81\)\
\-\ ewing\\ sarcoma\ \(0\)\
\-\ sarcoma\ \(742\)\
\-\ 42\\ year\\ old\\ man\\ with\\ back\\ pain\ \(1\)\
\-\ the\\ most\\ frequent\\ site\\ of\\ metastatic\\ disase\\ to\\ the\\ spine\\ is\\ to\\ the\\ highly\\ vascular\\ bone\\ marrow\\ of\\ vertebral\\ bodies\\.\\ vertebral\\ body\\ metastases\\ will\\ often\\ spread\\ into\\ the\\ region\\ of\\ the\\ pedicle\\ and\\ posterior\\ elements\\.\\ \ \(0\)\
\-\ initially\\,\\ fatty\\ marrow\\ is\\ replaced\\ with\\ tumor\\ cells\\.\\ the\\ normal\\ high\\ intensity\\ on\\ t1wi\\ from\\ fatty\\ marrow\\ is\\ replaced\\ by\\ a\\ lower\\ signal\\ intensity\\.\\ soon\\ after\\ there\\ is\\ loss\\ of\\ the\\ bony\\ trabeculae\\,\\ most\\ often\\ without\\ periosteal\\ reaction\\.\\ on\\ postcontrast\\ t1\\ tumor\\ within\\ the\\ vertebral\\ body\\ enhances\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ vertebral\\:\\ 0\\.09393878945589607\ \(0\)\
\-\ marrow\\:\\ 0\\.07831817955454562\ \(0\)\
\-\ replaced\\:\\ 0\\.07666224386058568\ \(0\)\
\-\ fatty\\:\\ 0\\.06157627485128633\ \(0\)\
\-\ disase\\:\\ 0\\.06121887794421179\ \(0\)\
\-\ body\\:\\ 0\\.057817994014355924\ \(0\)\
\-\ sarcoma\\:\\ 0\\.05284559902597558\ \(0\)\
\-\ intensity\\:\\ 0\\.0428982038386014\ \(0\)\
\-\ postcontrast\\:\\ 0\\.04241297376989089\ \(0\)\
\-\ trabeculae\\:\\ 0\\.04114685184771065\ \(0\)\
\-\ pedicle\\:\\ 0\\.03859320754128483\ \(0\)\
\-\ often\\:\\ 0\\.037867688173884057\ \(0\)\
\-\ soon\\:\\ 0\\.037151267508102576\ \(0\)\
\-\ t1wi\\:\\ 0\\.03652896085053531\ \(0\)\
\-\ ewing\\:\\ 0\\.03633332976048881\ \(0\)\
\-\ l3\\:\\ 0\\.03560165951286501\ \(0\)\
\-\ myeloma\\:\\ 0\\.03448174182122528\ \(0\)\
\-\ elements\\:\\ 0\\.03255822249250977\ \(0\)\
\-\ signal\\:\\ 0\\.03129269903156637\ \(0\)\
\-\ leukemia\\:\\ 0\\.030449316841133223\ \(0\)\
\-\ 42\\:\\ 0\\.030047792043294157\ \(0\)\
\-\ metastatic\\:\\ 0\\.02987651949466792\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.029668219734003434\ \(0\)\
\-\ frequent\\:\\ 0\\.029668219734003434\ \(0\)\
\-\ expansion\\:\\ 0\\.0292385294304056\ \(0\)\
\-\ soft\\:\\ 0\\.028901760611021527\ \(0\)\
\-\ spread\\:\\ 0\\.028704077755849156\ \(0\)\
\-\ highly\\:\\ 0\\.028576653181764455\ \(0\)\
\-\ into\\:\\ 0\\.028240643999440374\ \(0\)\
\-\ periosteal\\:\\ 0\\.028148225619227373\ \(0\)\
\-\ enhances\\:\\ 0\\.028030520353159505\ \(0\)\
\-\ bodies\\:\\ 0\\.027800931031903335\ \(0\)\
\-\ tumor\\:\\ 0\\.027669893077927932\ \(0\)\
\-\ most\\:\\ 0\\.027400488079556612\ \(0\)\
\-\ is\\:\\ 0\\.027333579504813053\ \(0\)\
\-\ reaction\\:\\ 0\\.02695169785302643\ \(0\)\
\-\ there\\:\\ 0\\.026494074093020598\ \(0\)\
\-\ deformity\\:\\ 0\\.025553611020251638\ \(0\)\
\-\ metastases\\:\\ 0\\.025352308680854058\ \(0\)\
\-\ site\\:\\ 0\\.025079942617289602\ \(0\)\
\-\ tissues\\:\\ 0\\.02435590782337009\ \(0\)\
\-\ initially\\:\\ 0\\.024152641279619306\ \(0\)\
\-\ cells\\:\\ 0\\.02379476870937498\ \(0\)\
\-\ extensive\\:\\ 0\\.023731636961449618\ \(0\)\
\-\ bony\\:\\ 0\\.023731636961449618\ \(0\)\
\-\ compression\\:\\ 0\\.022213523099305046\ \(0\)\
\-\ metastasis\\:\\ 0\\.022213523099305046\ \(0\)\
\-\ involvement\\:\\ 0\\.021749574004359836\ \(0\)\
\-\ back\\:\\ 0\\.019576849551024147\ \(0\)\
\-\ spine\\:\\ 0\\.01954238573614825\ \(0\)\
\-\ vascular\\:\\ 0\\.019456967138359003\ \(0\)\
\-\ t1\\:\\ 0\\.018808996779335025\ \(0\)\
\-\ will\\:\\ 0\\.01856584040541071\ \(0\)\
\-\ renal\\:\\ 0\\.017829691315681035\ \(0\)\
\-\ loss\\:\\ 0\\.01722544564214194\ \(0\)\
\-\ lymphoma\\:\\ 0\\.01695971273881587\ \(0\)\
\-\ abnormal\\:\\ 0\\.01692425166885355\ \(0\)\
\-\ carcinoma\\:\\ 0\\.016818942152887963\ \(0\)\
\-\ region\\:\\ 0\\.016761119633606335\ \(0\)\
\-\ high\\:\\ 0\\.01623990320192233\ \(0\)\
\-\ cell\\:\\ 0\\.016029449385982542\ \(0\)\
\-\ fracture\\:\\ 0\\.015646349515783184\ \(0\)\
\-\ mild\\:\\ 0\\.015626760096744005\ \(0\)\
\-\ anterior\\:\\ 0\\.015283283498352342\ \(0\)\
\-\ bone\\:\\ 0\\.014746074176804652\ \(0\)\
\-\ tissue\\:\\ 0\\.014065424919809678\ \(0\)\
\-\ man\\:\\ 0\\.014034248910347215\ \(0\)\
\-\ associated\\:\\ 0\\.014003212235470151\ \(0\)\
\-\ without\\:\\ 0\\.013972313655265\ \(0\)\
\-\ posterior\\:\\ 0\\.013678045477100336\ \(0\)\
\-\ lower\\:\\ 0\\.013346264370582379\ \(0\)\
\-\ after\\:\\ 0\\.012277786129230571\ \(0\)\
\-\ within\\:\\ 0\\.011320357002681122\ \(0\)\
\-\ which\\:\\ 0\\.011077392966962142\ \(0\)\
\-\ the\\:\\ 0\\.010560709248193637\ \(0\)\
\-\ on\\:\\ 0\\.010054041838408722\ \(0\)\
\-\ by\\:\\ 0\\.009881047939200518\ \(0\)\
\-\ normal\\:\\ 0\\.009302864268049313\ \(0\)\
\-\ from\\:\\ 0\\.008794692452459807\ \(0\)\
\-\ pain\\:\\ 0\\.007247278941185657\ \(0\)\
\-\ year\\:\\ 0\\.0066396199255063515\ \(0\)\
\-\ old\\:\\ 0\\.006075934700432323\ \(0\)\
\-\ to\\:\\ 0\\.0059315015061525865\ \(0\)\
\-\ \\,\\:\\ 0\\.0056397930316101534\ \(0\)\
\-\ of\\:\\ 0\\.004045270861041265\ \(0\)\
\-\ with\\:\\ 0\\.003250116002496937\ \(0\)\
\-\ in\\:\\ 0\\.00292636965375177\ \(0\)\
\-\ a\\:\\ 0\\.002754165290406953\ \(0\)\
\-\ \\.\\:\\ 0\\.001972196449852571\ \(0\)\
\-\ and\\:\\ 0\\.0012500625398070724\ \(0\)\
